tweenvest

IMPACT Therapeutics, Inc (SEHK: 7630)

Salud · Biotecnología · CN

9,12 HK$

+8,64 % hoy · -78,2 % 1 año

Ficha pública
Un resumen gratuito de IMPACT Therapeutics, Inc, con datos del 15 nov 2026. El análisis completo está en la app.Abrir en la app

IMPACT Therapeutics, Inc (SEHK: 7630) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 328,17 M $ y tiene 88 empleados.

En los últimos doce meses la acción ha bajado un 78,2 % y ha cotizado entre 7,87 y 47,98.

Tweenvest puntúa a IMPACT Therapeutics, Inc en cuatro factores: calidad 42/100, valor 70/100. Su punto más fuerte es valor.

Evolución de la cotización de 7630

15 may 2026 · 40,04Cierres semanales 8,51 – 40,0413 nov 2026 · 9,12

Cifras clave

Capitalización
328,17 M $
Ingresos (últ. 12 m)
17,40 M $
PER
-9,27
BPA
-1,44
Rent. por dividendo
—
Beta (5 años)
—
Máximo 52 semanas
47,98 HK$
Mínimo 52 semanas
7,87 HK$
Volumen medio (3 m)
—
Acciones en circulación
282,46 M
Empleados
88
Próximos resultados
—

Sobre IMPACT Therapeutics, Inc

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

ISIN
CNE100007LG4
Fundada en
2009
Cotiza desde
13 may 2026
Bolsa
The Stock Exchange of Hong Kong Ltd.
Divisa
HKD
EmpresaCapitalizaciónPrecioDía
Laekna, Inc.SEHK: 2105338,09 M $6,23 HK$-5,82 %
BioNote, Inc.KOSE: A377740336,90 M $4450,00 ₩-0,89 %
BioDlink International Company LimitedSEHK: 1875333,92 M $3,39 HK$+1,50 %
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.SZSE: 300313330,80 M $9,20 CN¥-3,97 %
GC Corp.KOSE: A005250325,65 M $9580,00 ₩-1,44 %
Eikon Therapeutics, Inc.NasdaqGS: EIKN324,03 M $5,98 $-0,99 %
Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA320,09 M $10,99 $-1,87 %
X4 Pharmaceuticals, Inc.NasdaqCM: XFOR318,59 M $3,12 $-1,58 %

Ver todas las empresas de biotecnología →